[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100188780":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":29,"centralContacts":33,"locations":33,"responsibleParty":34,"collaborators":33,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":33,"eligibilityCriteria":42,"healthyVolunteers":43,"sex":44,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":33,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":60,"whyStopped":33,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":33},{"fullName":5,"class":6},"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Canagliflozin (JNJ-28431754) + glyburide","EXPERIMENTAL","Each volunteer will receive a single dose of glyburide on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 4 through 8. On Day 9 volunteers will receive a single dose of glyburide in combination with a single dose of canagliflozin.",[13,14],"Drug: Glyburide","Drug: Canagliflozin (JNJ-28431754)",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Glyburide","One 1.25 mg tablet taken orally (by mouth) on Day 1 and Day 9.",[9],[22],"Micronase",{"type":17,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"Canagliflozin (JNJ-28431754)","One 200 mg tablet taken orally (by mouth) on Days 4 through 9.",[9],[28],"JNJ-28431754",[30],{"name":31,"affiliation":5,"role":32},"Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial","STUDY_DIRECTOR",null,{"type":35,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100188780","phase-1-a-study-to-assess-the-effects-of-canagliflozin-jnj-28431754-on-the-pharmacokinetics-pharmacodynamics-and-safety-of-glyburide-in-healthy-volunteers-100188780",false,"NCT01733108","A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Glyburide in Healthy Volunteers","An Open-Label Drug-Drug Interaction Study in Healthy Subjects to Explore the Effects of Multiple Doses of JNJ-28431754 on the Pharmacokinetics and Safety of Single Doses of Glyburide","Inclusion Criteria:\n\n* Volunteer must have a body mass index (BMI = weight in kg\u002Fheight in m2) between 18 and 30 kg\u002Fm2 (inclusive) and body weight not less than 50 kg Exclusion Criteria:\n* Volunteer has a history of or currently active illness considered to be clinically significant by the Investigator or any other illness that the Investigator considers should exclude the patient from the study or that could interfere with the interpretation of the study results\n* Volunteer has a fasting plasma glucose \\\u003C 100 mg\u002FdL (as measured by oral glucose tolerance test) and a 2-hour plasma glucose \\\u003C= 140 mg\u002FdL\n* History of smoking or use of nicotine-containing substances within the previous 6 months",true,"ALL","18 Years","45 Years",{"count":48,"type":49},29,"ACTUAL","INTERVENTIONAL",[52],"PHASE1","The purpose of this study is to determine how multiple doses of canagliflozin (JNJ-28431754) affect the pharmacokinetics (ie, how the body affects the drug) and pharmacodynamics (ie, how the drug affects the body) of a single dose of glyburide.",[55],"Healthy",[55,24,57,58,59],"Pharmacokinetics","Pharmacodynamics","Glyburide (MICRONASE)","COMPLETED","2012-12-11",{"date":63,"type":64},"2012-12-12","ESTIMATED",{"date":66,"type":33},"2008-07",{"date":68,"type":49},"2008-09",{"name":5,"class":6}]